Skip to main content
Premium Trial:

Request an Annual Quote

Aclara to Merge with ViroLogic

NEW YORK, June 1 (GenomeWeb News) - Aclara Biosciences and ViroLogic have signed a merger agreement to create a molecular diagnostics company for oncology and infectious diseases, the companies said today. The new company will be called ViroLogic.


Under the merger agreement, every share of Aclara stock will be exchanged for 1.7 shares of ViroLogic common stock as well as 1.7 contingent value rights, or CVR, for a total of $4.78 per share. The CVR includes a potential cash payment of up to $.85 per Aclara Share, and is contingent upon the ViroLogic stock price 12 months after the merger is closed.


ViroLogic said it would have $75 million in cash, cash equivalents and marketable securities after the closing of the merger, and prior to any payment made under the CVRs.


The companies will combine Aclara's eTag platform with ViroLogic's laboratory, patient testing and pharmaceutical drug development business. ViroLogic, of South San Francisco, Calif., markets a line of drug resistance tests for HIV and hepatitis.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.